Synopsys, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +65

Synopsys Stock (SNPS) Opinions on Earnings Beat - Quiver Quantitative

AI-generated analysis

πŸ“ˆ Synopsys Q1 2026 revenue reached $2.4 billion, marking a massive 65.52% increase compared to the prior year.

πŸ’Ό NVIDIA Corporation added $2.26 billion in shares to its portfolio, reinforcing Synopsys's status as a key AI design layer player.

πŸ“‰ UBS Asset Management removed $2.56 billion in shares (-73.6%) from its portfolio in Q4 2025.

πŸ›οΈ Representative Dan Newhouse purchased up to $15,000 of SNPS stock on December 31, 2025.

πŸ“Š Wall Street analysts maintain a median price target of $560 with a mix of Buy and Overweight ratings.

πŸ’° Adjusted EPS highlighted strong execution strength alongside the revenue surge in design automation.

πŸš€ Market enthusiasm centers on Synopsys's essential tools for AI and data center advances despite dips from all-time highs.

πŸ“‰ Price T Rowe Associates removed $519 million in shares (-33.3%) during the fourth quarter of 2025.

πŸ” Insider trading shows net selling by C-suite executives, with CFO Shelagh Glaser selling $1.68 million worth of stock.

πŸ“‰ FMR LLC added $792 million in shares (+29.1%) to its portfolio, contrasting with heavy selling from other institutions.

Bullish Signals
  • Revenue soared past expectations with a sharp 65.52% year-over-year increase to $2.4 billion.
  • NVIDIA's massive $2.26 billion investment signals strong institutional confidence in Synopsys's AI ecosystem role.
  • The company is positioned as an essential upstream partner for the ongoing semiconductor capex surge.
  • Analyst consensus remains bullish with a median price target of $560 and multiple 'Buy' ratings from major firms.
  • Social media sentiment was highly positive, emphasizing robust AI-driven demand and margin expansion.
  • Members of Congress, including Representative Dan Newhouse, have purchased shares in the past six months.
Risk Factors
  • UBS Asset Management drastically reduced its position by $2.56 billion (-73.6%), indicating a significant loss of confidence from a major holder.
  • Multiple large institutional investors including Price T Rowe, Pictet, and Wellington Management sold over $1 billion combined in Q4 2025.
  • Insider trading data reveals net selling by top executives, with the Chief Accounting Officer and CFO collectively selling nearly $9.5 million worth of shares.
  • Some analysts have set lower price targets, such as Piper Sandler at $430 and Wells Fargo at $450, suggesting potential downside risk.
  • One firm, Exane BNP Paribas, issued an 'Underperform' rating in October 2025, contrasting with the majority of recent buy ratings.
Full Analysis
Synopsys (SNPS) reported a significant earnings beat in Q1 2026, with revenue surging to $2.4 billion, representing a 65.52% year-over-year increase. The company demonstrated robust execution and strong AI-driven demand, particularly within its design automation segment, which drove margin expansion. Social media sentiment was overwhelmingly positive, framing the results as a vote of confidence in Synopsys's critical role within the semiconductor ecosystem. Institutional activity highlighted a major shift in portfolio composition during Q4 2025. NVIDIA Corporation made a substantial investment, adding approximately $2.26 billion worth of shares to its position, signaling strong belief in Synopsys as an essential upstream partner for AI and data center advancements. Conversely, several major asset managers including UBS Asset Management, Pictet, and Price T Rowe significantly reduced their holdings, with UBS alone selling over $2.5 billion in shares. Analyst sentiment remains mixed but generally bullish, with a median price target of $560 set by 11 analysts covering the stock. Major firms like Morgan Stanley, Rosenblatt, and Citigroup maintain 'Buy' or 'Overweight' ratings, while some targets range from $430 to $650. Insider trading data shows net selling by top executives over the last six months, though this is offset by significant purchases from members of Congress and specific institutional buyers like FMR LLC.